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Volume 58, Number 5 Abstracts 1435Objectives: Readmission following vascular surgery intervention is
frequent, costly, and often considered preventable. Vascular surgery
outcomes have recently been scrutinized by Medicare, given high rates of
readmission. We determine patient and clinical characteristics that predict
readmission in a cohort of vascular surgery patients.
Methods: From 2009 to 2013, the medical records of all patients
(n ¼ 2505) undergoing interventions by the vascular surgery service at
a single tertiary care institution were retrospectively reviewed. Sociodemo-
graphic and clinical characteristics were examined for association with 30-
day readmission.
Results: The 30-day readmission rate to the same institution was
9.7% (n ¼ 244). Procedures most likely to result in readmission were
below-knee (25%), foot (22%), and toe amputations (19%), as well as
lower extremity revisions (22%). Patients covered by Medicaid
(16.8%) and Medicare (10.0%) were most likely to be readmitted fol-
lowed by fee-for-service (9.5%), self-pay (8.0%), and health maintenance
organization (5.5%; P < .05). Patients urgently admitted were more
likely to be readmitted (16.2%) than electively admitted patients
(9.1%; P < .01). Patient severity (rated using 3M APR DRG software)
predicted readmission (16.2% high vs 6.2% low severity; P < .01). Initial
length of stay was longer for readmitted than nonreadmitted patients
(8.5 vs 6.1 days, respectively; P < .01). Intensive care unit admission
during initial hospitalization was moderately associated with higher
readmission rates (18.3% with vs 9.5% without intensive care unit
stay; P < .05). Discharge destination was also a strong predictor of
readmission (rehabilitation, 19.2%; skilled nursing facility, 16.2% vs
home, 6.2%; P < .01). The effects of urgent admission, illness severity,
length of stay, and discharge destination persisted in multivariable
logistic regression.
Conclusions: To reduce readmission rates effectively, institutions
must identify high-risk patients. Efforts should focus on subgroups under-
going selected interventions (amputations, vascular revisions), as well as
urgent admissions and those with extended hospital stays. Patients in
need of postacute care upon discharge are especially prone to readmission,
requiring special attention to discharge planning and coordination of post-
discharge care.
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Objectives: To compare the morbidities, mortality, length of stay,
and total cost between simultaneous and staged carotid endarterectomy
(CEA) and coronary artery bypass grafting (CABG).
Methods: Utilizing the Nationwide Inpatient Sample (NIS), we
studied all the patients that underwent CEA and CABG between 2008
and 2010. International Classiﬁcation of Disease, Ninth Revision codes
were used to look for procedure types, comorbidities, and complications.
Data analysis was done using SPSS v.19 (IBM, Armonk, NY); statistical
signiﬁcance was deﬁned as P < .05.
Results: Both CEA and CABG (CEA/CABG) was done in 8568
patients. CEA/CABG group was categorized into Simultaneous CEA/
CABG (SmCC; same day; 4534 [52.9%]), and Staged CEA/CABG
(StCC; different days, same admission; 2209 [25.8%]); 1825 (21.3%)Table. Adjusted and nonadjusted comparison of simultaneous and staged carot
Nonadjusted
Simultaneous Staged P
No. 4534 2209
LOS, days (median) 9 13 <.01
Total cost, USD (median) 124,544 171,094 <.01
Mortality 181/4% 98/4% .390
Myocardial infarction 1099/24% 558/25% .366
Stroke 90/2% 49/2% .528
LOS, Length of stay.
aStandardized coefﬁcient.patients were excluded (deﬁcient coding). When SmCC was compared
with StCC, Length of stay (LOS) and total charges were signiﬁcantly
higher in StCC; however, no signiﬁcant difference was found in
mortality, in-hospital myocardial infarction, or postoperative stroke.
After adjustment for comorbidities (hypertension, diabetes mellitus,
congestive heart failure, smoking and peripheral vascular disease),
comparison of SmCC and StCC yielded comparable results for LOS
and total charges, but no signiﬁcant differences in mortality, in-hospital
myocardial infarction, and postoperative stroke between SmCC and
StCC (Table).
Conclusions: In patients with combined CEA/CABG, simultaneous
surgery carries lower charges, LOS, mortality and stroke rate as compared
with staged procedures in the same admission.
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Objectives: This study evaluated amputation-free-survival in patients
identiﬁed utilizing Plavix (Clopidogrel) following their lower extremity
endovascular revascularization (LER).
Methods: Patients 65 years of age and greater undergoing LER were
identiﬁed from MedPAR ﬁles (2007 to 2008) utilizing International Classi-
ﬁcation of Disease, Ninth Revision codes. Demographics, comorbidities,
and severity of disease (claudication, rest pain, ulceration/gangrene
[UG]) are evaluated. Postprocedural use of Plavix was identiﬁed using the
National Drug Code directory and Part D ﬁles. Outcomes were measured
using c2 analysis, multivariable logistic regression, Kaplan-Meier, and Cox
regression.
Results: A total of 14,353 patients were identiﬁed: 7189 with clau-
dication (50.1%), 1467 with rest pain (10.2%), 5697 with UG (39.7%).
Of these, 5416 (37.7%) patients were identiﬁed using Plavix after LER.
Overall, patients initiated on Plavix had lower amputation rates at 30
days (10.34% vs 14.09%; P < .0001), 90 days (14.05% vs 18.71%; P
< .0001), and 1 year (19.68% vs 24.06%; P < .0001). Multivariate
logistic regression analysis adjusted by age, gender, race, and comorbid-
ities conﬁrmed that non-Plavix users were more likely to undergo ampu-
tation at 30 days (odds ratio [OR], 1.28; 95% conﬁdence interval [CI],
1.14-1.43), 90 days (OR, 1.29; 95% CI, 1.16-1.43), and 1 year (OR,
1.16; 95% CI, 1.05-1.28). Males, blacks, congestive heart failure, dia-
betes, and renal failure were signiﬁcant predictors of amputation. In
c2, logistic regression, and Cox regression analyses, Plavix did not signif-
icantly affect amputation rates in patients with claudication or rest pain.
Patients with UG who did not receive Plavix were signiﬁcantly more
likely to undergo amputation at 30 days (OR, 1.29; 95% CI, 1.14-
1.45), 90 days (OR, 1.28; 95% CI, 1.15-1.43), and 365 days (OR,
1.19; 95% CI, 1.07-1.31).
Conclusions: Utilization of Plavix after LE endovascular revasculari-
zation was associated with lower rates of amputation, yet only 38% of the
Medicare population was identiﬁed as using Plavix after intervention.
Patients with UG beneﬁted the greatest with signiﬁcantly greater amputa-
tion-free survival and overall survival. Prospective randomized trials are
needed to assess the suggested beneﬁts of Plavix on amputation-free survival
after LE endovascular revascularization.id endarterectomy (CEA) and coronary artery bypass grafting (CABG)
Adjusted
Odds ratio P 95% conﬁdence interval
0.182a <.01 3.178 3.965
0.070a <.01 14641 24291
0.943 .671 0.720 1.236
0.994 .924 0.880 1.123
0.878 .478 0.613 1.258
